Higher red cell transfusion threshold offers no advantage for treating preterm infants

Very low birthweight infants often need blood transfusions to survive. A study suggests that providing a higher threshold of red cells within accepted limits offers no advantage in survival or reduction in neurological impairment over a lower threshold.

Higher red cell transfusion threshold offers no advantage for treating preterm infants. Photo: Hush Naidoo/Unsplash

The research was conducted by Haresh Kirpalani, B.M., of the University of Pennsylvania, Philadelphia, and colleagues and was funded by the NIH’s Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD), National Heart, Lung, and Blood Institute, and National Center for Advancing Translational Sciences.

Very preterm infants (born before 29 weeks of pregnancy) and those weighing less than 1,000 grams (slightly more than 2 pounds) are at high risk for anemia because of their early stage of development, reduced ability to produce red blood cells and need for increased blood sampling as part of their intensive medical care.

Previous studies suggest that anemic infants would have a lower risk of death, cognitive delay, cerebral palsy and hearing and vision loss if they received transfusions leading to higher hemoglobin thresholds within the currently accepted range.

Measuring hemoglobin, a protein produced in red blood cells, indicates the proportion of red blood cells. Hemoglobin transfusion thresholds for preterm infants vary according to weight, stage of maturity and other factors.

Of 845 infants assigned to a higher hemoglobin threshold, 50.1% died or survived with a neurodevelopmental impairment, compared to 49.8% of 847 infants assigned to a lower threshold.

When the two component outcomes were evaluated separately, the two groups also had similar rates of death (16.2% vs. 15%) and of neurodevelopmental impairment (39.6% vs 40.3%).

The authors conclude that a higher hemoglobin threshold increased the number of transfusions, but did not improve the chance of survival without neurodevelopmental impairment. (National Institutes of Health)

YOU MAY ALSO LIKE

Study uncovers blood vessel damage and inflammation in COVID-19 patients’ brains but no infection

Results from a study of 19 deceased patients suggests brain damage is a byproduct of a patient’s illness.

Study links metabolic syndrome to higher cardiovascular risk in patients with psoriasis

Psoriasis, a chronic inflammatory skin disease, has long been known to increase the risk of cardiovascular disease, which includes heart attack and stroke.

New Method for Imaging Exhaled Breath Could Provide Insights into COVID-19 Transmission

A new method for visualizing breath that is exhaled while someone is speaking or singing could provide important new insights into how diseases such as COVID-19 spread and the effectiveness of face masks.

Cataract surgery in infancy increases glaucoma risk

Children who undergo cataract surgery as infants have a 22% risk of glaucoma 10 years later, whether or not they receive an intraocular lens implant.

Researchers discover brain area crucial for recognizing visual events

Researchers at the National Eye Institute report that a brain region in the superior temporal sulcus is crucial for processing and making decisions about visual information.

Gene therapy injection in one eye surprises scientists by improving vision in both

Injecting a gene therapy vector into one eye of someone suffering from LHON, the most common cause of mitochondrial blindness, significantly improves vision in both eyes, scientists have found.